# A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents

> **NCT01596088** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kissei Pharmaceutical Co., Ltd.** · enrollment: 2 (actual)

## Conditions studied

- Extravasations of Anthracycline Anti-cancer Agents

## Interventions

- **DRUG:** Dexrazoxane

## Key facts

- **NCT ID:** NCT01596088
- **Lead sponsor:** Kissei Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2014-01
- **Final completion:** —
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2015-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01596088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01596088, "A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01596088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*